Objective To compare the clinical efficacy of ultrasound-guided lauromacrogol and anhydrous etha-nol in the treatment of thyroid cysts and analyze the related influencing factors.Method A retrospective analysis was conducted on the medical records of 73 patients with thyroid cystic sclerosis treated at the First Affiliated Hospital of U-niversity of Science and Technology of China from May 2018 to January 2023.Observation group of 36 cases,treated with lauromacrogol;a control group of 37 cases were treated with anhydrous ethanol.The incidence of complications such as intraoperative and postoperative pain and sound changes,as well as the symptom scores,cosmetic scores,thyroid function changes,and cyst volume reduction rate(VRR)of two groups of patients were compared.Results The incidence of in-traoperative pain in the observation group(2.8％)was significantly lower than that in the control group(35.1％),and the difference was statistically significant(P＜0.05).Within one year after surgery,there was no statistically significant difference(P＞0.05)in symptom scores,cosmetic scores,thyroid function indicators,and cyst VRR between the two groups.The results of multiple logistic regression analysis showed that the concentration of vascular endothelial growth factor(VEGF)in the cystic fluid was an independent risk factor affecting VRR at 12 months after treatment(P＜0.05).Conclusions Both lauromacrogol and anhydrous ethanol sclerotherapy can effectively reduce the volume of thy-roid cysts,but lauromacrogol as a sclerotherapy agent can better reduce the incidence of pain and complications in pa-tients during surgery.The concentration of VEGF in the cystic fluid is an independent risk factor for VRR at 12 months after sclerotherapy.
维普
万方数据